An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Diagnostic use
- Acronyms EVOLUTION
- Sponsors Merck Sharp & Dohme
- 10 Aug 2017 Planned End Date changed from 1 Sep 2017 to 5 Sep 2017.
- 12 Jun 2017 Planned End Date changed from 2 Oct 2017 to 1 Sep 2017.
- 12 Jun 2017 Planned primary completion date changed from 24 Jul 2017 to 25 Jun 2017.